Compass Therapeutics, Inc. (CMPX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated August 11, 2025, announces the financial results for Compass Therapeutics, Inc. for the quarter and six months ended June 30, 2025. The company is an emerging growth company incorporated in Delaware with principal executive offices in Boston, Massachusetts.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K.
Material Changes
No specific material changes versus the prior comparable period are quantified in this filing. The report serves as a notification that the results have been issued and are available in the attached exhibits.
Guidance, Outlook, and Management Commentary
Management commentary and corporate presentations are provided in the following exhibits, which are incorporated by reference:
- Exhibit 99.1: Press Release dated August 11, 2025.
- Exhibit 99.2: Slides from the second quarter earnings call.
- Exhibit 99.3: August 2025 corporate presentation.
Note: Information in Item 7.01 (including Exhibit 99.2) is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference in other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 for specific revenue, net loss, and cash position figures for the quarter and six months ended June 30, 2025.
- Examine Exhibit 99.2 and Exhibit 99.3 for updated clinical trial timelines, regulatory milestones, and forward-looking guidance.
- Verify the company's cash runway and burn rate as disclosed in the full press release, as this is critical for an emerging growth biotech firm.
- Confirm any changes in the development status of key therapeutic candidates mentioned in the earnings call slides.